


Attorney Docket No.: 6296.204-US

1646
#8
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Van Den Berghe, Greta

Serial No.: 09/853,193

Group Art Unit: 1646

Filed: May 11, 2001

Examiner: To be assigned

Confirmation No: 5893

For: Methods and Preparations For Curing Clinically Ill Patients

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir;


I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (57 Total)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on January 23, 2002.

Sylvia Gonzalez
(name of person mailing paper)

(signature of person mailing paper)

IDS/#8
J 2/26/02



Attorney Docket No.: 6296.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Van Den Berghe, Greta

Application No.: 09/853,193

Group Art Unit: 1646

Filed: May 11, 2001

Examiner: To be assigned

Confirmation No: 5893

For: Methods and Preparations For Curing Clinically Ill Patients

TECH CENTER 1600/2900

FEB 15 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. Abstract, SU 19925044940, Derwent Accession No. 1996-096019[10] Novos Blood Circulation Pathology Institute.
2. K.O. Case et al., "Nutrition Support in the Critically Ill Patient", Crit. Care Nurs Q 2000:22(4), pgs. 75-89 (2000)

3. Y. Sakurai et al., "Stimulation of Muscle Protein Synthesis by Long-Term Insulin Infusion in Severely Burned Patients", *Annals of Surgery*, Vol. 222, No. 3, pgs. 283-297 (1995)
4. Iapichino et al., "L'usage de l'insulin comme agent anabolisant doit-il être préconisé chez le sujet dénutri ou agressé" *Nutr. Clin. Metabol.* Vol. 10, pgs. 243-252
5. K.C. McCowen et al., "Stress-Induced Hyperglycemia", *Critical Care Clinics* Vol. 17, No:1, pgs. 107-124 (2001)
6. Press Release "Clinical Study demonstrates impressive life-saving effect of insulin by tight control of glucose in intensive care patients" pgs. 1-3 (November 8, 2001)
7. UK Prospective Diabetes Study (UKPDS) Group "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" *The Lancet* Vol. 352, pgs. 837-853 (1998)
8. Nathan et al, "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" *The New England Journal of Medicine*, Vo. 329, No. 14, pgs. 977-986 (1993)
9. G. Van Den Berghe et al., "Intensive Insulin Therapy In Critically Ill Patients" *The New England Journal of Medicine* Vol. 345, No.19, pgs. 1359-1367 (2001)
10. Zochodne et al "Critical Illness Polyneuropathy-A Complication of Sepsis and Multiple Organ Failure" *Brain* Vol. 110, pgs. 819-842 (1987)
11. Leijten et al, "Critical Illness Polyneuropathy - A review of the literature, definition and pathophysiology" *Clinical Neurology and Neurosurgery* Vol. 96, pgs. 10-19 (1994)
12. C.F. Bolton "7.8 Acute Weakness" *7 The Neurological System*, pgs. 490-495
13. C.F. Bolton, "Sepsis and the systemic inflammatory responses syndrome: Neuromuscular manifestations " *Crit Care Med* Vol. 24 No. 8, pgs 1408-1416 (1996)
14. R.R. Wolfe et al., "Glucose Metabolism in Man: Responses to Intravenous Glucose Infusion" *Metabolism*, Vol. 28 No. 3. pgs. 210-220 (1979)
15. R. R. Wolfe et al., "Effect of Severe Burn Injury on Substrates Cycling By Glucose and Fatty Acids" *The New England Journal of Medicine* Vol. 317, No. 7, pgs. 403-408 (1987)
16. R. E. Shangraw et al., "Differentiation Between Septic and Postburn Insulin Resistance", *Metabolism*, Vol. 38, No. 10. pgs. 983-989(1989)
17. B.A. Mizock et al., "Alterations in Carbohydrate Metabolism During Stress: A Review of the Literature" *The American Journal of Medicine*, Vol. 98 pgs. 75-84 (1995)
18. K.C. McCowen et al., "Stress-Induced Hyperglycemia" *Critical Care Clinics*, Vol. 17, Number 1, pgs. 107-124 (2001)

19. R. Fietsman et al., "Complications of Coronary Artery Surgery in Diabetic Patients" *The American Surgeon* Vol. 57, pgs. 551-557 (1991)
20. P.A.O'Neill et al., "Stress Hormone and Blood Glucose Response Following Acute Stroke in the Elderly" *Stroke*, Vol. 22, pgs. 842-847 (1991)
21. J.F. Scott et al., "Glucose Potassium Insulin Infusions in the Treatment of Acute Stroke Patients with Mild to Moderate Hyperglycemia" *The Glucose Insulin in Stroke Trial (GIST)* *Stroke*, Vol.30 pgs. 793-799 (1999)
22. K. Malmberg et al., "Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction" *Circulation* Vol. 99, pgs. 2626-2632 (1999)
23. K. Malmberg, "Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus" *BMJ*, Vol. 314:1512, pgs. 1-12 (1997)
24. K. Malmberg et al., "Randomized Trial of Insulin-Glucose Infusion Followed by Subcutaneous Insulin Treatment in Diabetic Patients With Acute Myocardial Infarction (GIGAMI Study): Effects on Mortality at 1 Year" *J. Am Coll Cardio* Vol. 26 pgs. 57-65 (1995)
25. G. Van Den Berghe et al., "Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness" *The Journal of Clinical Endocrinology & Metabolism* Vol. 84, No. 4 pgs. 1311-1323(1999)
26. G. Van Den Berghe et al., "A Paradoxical Gender Dissociation within the Growth Hormone/Insulin-Like Growth Factor I Axis during Protracted Critical Illness" *The Journal of Clinical Endocrinology & Metabolism* Vol. 85. No. 1, pgs. 183-192(2000)
27. A. Ortiz et al., "Expression of Apoptosis-Regulatory Genes in Renal Proximal Tubular Epithelial Cells Exposed to High Ambient Glucose and In Diabetic Kidneys" *Journal of Investigative Medicine* Vol. 45, No. 2, pgs. 50-56 (1997)
28. Gerard Said et al., "Severe Early-Onset Polyneuropathy in Insulin-Dependent Diabetes Mellitus" *The New England Journal of Medicine* Vol. 326 No. 19 pgs. 1257-1263 (1992)
29. Wiley W. Souba "Nutritional Support" *The New England Journal of Medicine* Vo. 336 No. 1. pgs. 41-48 (1997)
30. W.A. Knaus et al., "APACHE II: A severity of disease classification system" *Critical Care Medicine* Vo. 13. No. 10. pgs. 818-829 (1985)
31. D.R. Miranda et al., "Simplified Therapeutic Intervention Scoring System: The TISS-28 items-Results from a multicenter study" *Crit Care Med*. Vol. 24, No. 1. pgs. 64-73 (1996)
32. A. R. Keene et al, "Therapeutic Intervention Scoring System: Update 1983" *Crit Care Med*. Vol. 11. No. 1. pgs. 1-3 (1983)
33. W.A. Knaus "Measuring the Glasgow Coma Scale In the Intensive Care Unit: Potentials and Pitfalls" *Intensive Care World* page. 102

34. M.P. Weinstein et al., "The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults" *Clinical Infectious Diseases*. Vol. 24. pgs. 584-602 (1997)
- ✓ 35. M.P. Weinstein et al., "Clinical Importance of Identifying Coagulase-Negative Staphylococci Isolated from Blood Cultures: Evaluation of MicroScan Rapid and Dried Overnight Gram-Positive Panels versus a Conventional Reference Method" *Journal of Clin. Microbiol.* Vol. 36. No. 7 pgs. 2089-2092 (1998)
36. C.S. Levetan et al., "Hospital Management of Diabetes" *Acute Complications of Diabetes* Vol. 29. No. 4. pgs. 745-770(2000)
37. J. Takala et al., "Increased Mortality Associated With Growth Hormone Treatment in Critically Ill Adults" *The New England Journal of Medicine* Vol. 341. Number 11. pgs. 785-792 (1999)
38. K.G.M.M. Albert et al., "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation" *Diabetic Medicine* Vol. 15. pgs. 539-543 (1998)
39. S.E. Capes et al., "Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview" *The Lancet* Vol. 355. pgs. 773-778 (2000)
40. G.R. Bernard et al., "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis" *The New England Journal of Medicine* Vol. 344, No. 10. pgs. 699-709 (2001)
41. E.J. Rayfield et al., "Infection and Diabetes: The Case for Glucose Control" *The American Journal of Medicine* Vol. 72, pgs. 439-450 (1982)
42. S.E. Geerlings et al., "Immune dysfunction in patients with diabetes mellitus (DM)" *FEMS Immunology and Medical Microbiology* Vol. 26, pgs. 259-265 (1999)
43. A.J. Rassias et al., "Insulin Infusion Improves Neutrophil Function in Diabetic Cardiac Surgery Patients" *Anesth. Analg.* Vol. 88, pgs. 1011-1016 (1999)
44. M.R. Losser et al., "Glucose modulates hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits" *The American Physiological Society*, pgs. 1566-1574 (1997)
45. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group "Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial" *The Lancet* Vol. 356, pgs. 2139-2143 (2000)
46. A. Lassnigg et al., "Lack of Renoprotective Effects of Dopamine and Furosemide during Cardiac Surgery" *J. Am Soc. Nephrol* Vol. 11, pgs. 97-104 (2000)
47. J. Lewis et al., "Atrial Natriuretic Factor in Oliguric Acute Renal Failure" *American Journal of Kidney Diseases*, Vol. 36, No. 4. pgs. 767-774 (2000)

48. Correspondence "Acute Renal Failure" The New England Journal of Medicine Vol. 335, No. 17, pgs. 1320-1322 (1996)
49. R.S. Jones et al., "Insulin's Effect on Bile Flow and Lipid Excretion During Euglycemia and Hypoglycemia" Digestive Diseases and Sciences Vol. 29, No. 1, pgs. 33-39 (1984)
50. J.J. Garcia-Marin et al., "Diabetes-Induced Cholestasis in the Rat: Possible Role of Hyperglycemia and Hypoinsulinemia" Hepatology, Vol. 8, No. 2, pgs. 332-340 (1988)
51. Per Sidenius "The Axonopathy of Diabetic Neuropathy" Diabetes, Vol. 31, pgs. 356-363 (1982)
52. A.A. Ferrando et al., "A Submaximal Dose of Insulin Promotes Net Skeletal Muscle Protein Synthesis in Patients With Severe Burns" Annals of Surgery. Vol. 229, No. 1., pgs. 11-18 (1999)
53. T.J. Orchard "From Diagnosis and Classification to Complications and Therapy" Diabetes Care, Vol. 17, No. 4, pgs. 326-338 (1994)
54. G. Hawthorne et al., "Outcome of pregnancy in diabetic women in northeast England and in Norway, 1994-7" BMJ. Vol. 321. pgs. 730-731 (2000)
55. WO 00/16797
56. US 5,691,386
57. US 5,821,217


An English language translation of the Iapichino et al reference listed above as reference 4 will be provided to the Patent Office as soon as it becomes available.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: January 23, 2002


Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE